Aethlon Medical Inc (AEMD) 0.2189 $AEMD
SeeThruEquity Issues Quarterly Update Note on Aethlon Medical, Inc.
ACCESSWIRE - Fri Feb 13, 8:00AM CST
New York, NY / ACCESSWIRE / February 13, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update note on Aethlon Medical, Inc. (OTC:AEMD). Aethlon Medical, Inc. ("Aethlon"
is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On February 10, 2015, Aethlon reported results for F3Q15 (ended December 31, 2014). Highlights of the quarter include:
Aethlon Medical, Inc. - A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
PR Newswire - Thu Feb 12, 2:16PM CST
Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier(R)"
ACCESSWIRE - Thu Feb 12, 2:09PM CST
New York, NY / ACCESSWIRE / February 12, 2015 / Aethlon Medical, Inc. (OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens"
ACCESSWIRE - Thu Feb 05, 8:16AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2015 / Aethlon Medical, Inc. (OTCQB: AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Mr. James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical wins US FDA's approval of Ebola treatment protocol with Aethlon Hemopurifier
M2 - Mon Jan 05, 6:17AM CST
Therapeutic devices company Aethlon Medical (Other OTC:AEMD) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a clinical protocol to treat Ebola-infected individuals in the US with the Aethlon Hemopurifier.
Aethlon Medical Announces Approval of Ebola Treatment Protocol
PR Newswire - Fri Jan 02, 6:15AM CST
Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. In the treatment of viral pathogens, the Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:23AM CST
Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study
PR Newswire - Thu Dec 11, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 8.80 (+0.40), NLNK: 38.84 (+1.51), OSUR: 8.13 (+0.06)
Aethlon Medical Inc: Total Scam Or Legit Company?
Matthew Finston - at Seeking Alpha - Mon Dec 08, 2:27PM CST
Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST
JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99), IXJ: 104.21 (+0.61), IRY: 49.63 (+0.34)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.61 (+0.01), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
PR Newswire - Tue Dec 02, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
Aethlon Medical ships first Hemopurifier to Biocontainment Unit at the Nebraska Medical Center in aid of Ebola patients in the US
M2 - Thu Nov 27, 6:14AM CST
Therapeutic devices company Aethlon Medical (NASDAQ:OTCQB:AEMD) disclosed on Wednesday the shipment of four Hemopurifier therapy in support of future Ebola virus infections in the US.
Aethlon Medical expects USD3.3m from sale of units
M2 - Thu Nov 27, 6:04AM CST
Medical device company Aethlon Medical (Other OTC:AEMD) reported on Wednesday an agreement to raise approximately USD3.3m from the sale of units at a price of USD0.30 per unit.
Aethlon Medical Announces $3.3 Million Equity Investment
PR Newswire - Wed Nov 26, 4:16PM CST
Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it has entered into a definitive agreement to raise approximately $3.3 million at a price of $0.30 per unit. The investment is being made by one institutional healthcare focused investor. Each unit consists of one common share and one and one-fifth of a common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of $0.30 for a period of five years from closing.
Aethlon ships Hemopurifiers to Nebraska Med Center
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:14AM CST
Aethlon Medical Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States
PR Newswire - Wed Nov 26, 7:30AM CST
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.
Medical Advances & Technology Challenges Fueling Volume Into Small Cap Stocks
ACCESSWIRE - Tue Nov 25, 7:01AM CST
Boca Raton, FL / ACCESSWIRE / November 25, 2014 / 2015 is just around the corner and yet futuristic views are not so far away. Medical technology moves at great strides forward while the Digital Communications continue to present challenges and opportunities.
SeeThruEquity Issues Quarterly Update Note on Aethlon Medical, Inc.
ACCESSWIRE - Fri Feb 13, 8:00AM CST
New York, NY / ACCESSWIRE / February 13, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update note on Aethlon Medical, Inc. (OTC:AEMD). Aethlon Medical, Inc. ("Aethlon"
is a medical device company focused on creating innovative devices that address unmet medical needs in cancer, infectious disease and other life-threatening conditions. On February 10, 2015, Aethlon reported results for F3Q15 (ended December 31, 2014). Highlights of the quarter include: Aethlon Medical, Inc. - A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier®
PR Newswire - Thu Feb 12, 2:16PM CST
Aethlon Medical, Inc. (OTCQB: AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier(R)"
ACCESSWIRE - Thu Feb 12, 2:09PM CST
New York, NY / ACCESSWIRE / February 12, 2015 / Aethlon Medical, Inc. (OTCQB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical, Inc. - "The Launch of a Clinical Program That Re-Thinks the Treatment of Viral Pathogens"
ACCESSWIRE - Thu Feb 05, 8:16AM CST
NEW YORK, NY / ACCESSWIRE / February 5, 2015 / Aethlon Medical, Inc. (OTCQB: AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO Mr. James Joyce. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Aethlon Medical wins US FDA's approval of Ebola treatment protocol with Aethlon Hemopurifier
M2 - Mon Jan 05, 6:17AM CST
Therapeutic devices company Aethlon Medical (Other OTC:AEMD) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for a clinical protocol to treat Ebola-infected individuals in the US with the Aethlon Hemopurifier.
Aethlon Medical Announces Approval of Ebola Treatment Protocol
PR Newswire - Fri Jan 02, 6:15AM CST
Aethlon Medical, Inc. (AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the United States Food and Drug Administration (FDA) has approved a clinical protocol to treat Ebola-infected individuals in the U.S. with the Aethlon Hemopurifier®. In the treatment of viral pathogens, the Hemopurifier® is a first-in-class bio-filtration device designed for the single-use removal of viruses and shed glycoproteins from the circulatory system of infected individuals. The device targets antiviral drug resistance and serves as a first-line countermeasure against Ebola and other viruses that are not addressed with proven drug therapies.
FDA clears Aethlon's Hemopurifier IDE supplement to include Ebola
Seeking Alpha - at Seeking Alpha - Wed Dec 31, 6:23AM CST
Aethlon Medical Initiates Patient Recruitment for FDA Approved Clinical Study
PR Newswire - Thu Dec 11, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced the initiation of patient recruitment to support a clinical feasibility study of Hemopurifier® therapy that is being conducted at DaVita Med Center Dialysis in Houston, Texas. The study, which will enroll individuals infected with Hepatitis C virus (HCV) who are also receiving chronic dialysis therapy, is being conducted under an Investigational Device Exemption (IDE) approved by the United States Food and Drug Administration (FDA). A detailed description of the study, including treatment protocol and patient inclusion/exclusion criteria can be accessed online at www.clinicaltrials.gov.
Unveiled House Spending Bill Bullish For Ebola Stocks
Matthew Finston - at Seeking Alpha - Wed Dec 10, 8:46AM CST
NVAX: 8.80 (+0.40), NLNK: 38.84 (+1.51), OSUR: 8.13 (+0.06)
Aethlon Medical Inc: Total Scam Or Legit Company?
Matthew Finston - at Seeking Alpha - Mon Dec 08, 2:27PM CST
Hydration could save many Ebola victims
Seeking Alpha - at Seeking Alpha - Fri Dec 05, 6:19AM CST
JNJ: 99.62 (+1.18), BCRX: 10.06 (-0.09), HEB: 0.25 (+0.01), SRPT: 12.76 (+0.11), MRK: 58.81 (-0.07), NLNK: 38.84 (+1.51), TKMR: 21.45 (-0.22), GSK: 47.94 (+1.99), IXJ: 104.21 (+0.61), IRY: 49.63 (+0.34)
Biotech Stock Mailbag: Aethlon Medical, Oxigene, Sarepta
at The Street - Fri Dec 05, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care.
OXGN: 1.61 (+0.01), BMRN: 100.76 (+1.98), RNA: 18.65 (unch), SRPT: 12.76 (+0.11)
Aethlon Medical® Reports Rapid and Sustained Virologic Response Rates in Hepatitis C (HCV) Treated Patients
PR Newswire - Tue Dec 02, 6:15AM CST
Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today reported final clinical outcomes, including rapid virologic response (RVR) and sustained virologic response (SVR) rates, in Hepatitis-C virus (HCV) infected individuals who received Hemopurifier® therapy during a clinical study conducted at the Medanta Medicity Institute in India. Aethlon is now preparing to launch its first human clinical studies in the United States.
Aethlon Medical ships first Hemopurifier to Biocontainment Unit at the Nebraska Medical Center in aid of Ebola patients in the US
M2 - Thu Nov 27, 6:14AM CST
Therapeutic devices company Aethlon Medical (NASDAQ:OTCQB:AEMD) disclosed on Wednesday the shipment of four Hemopurifier therapy in support of future Ebola virus infections in the US.
Aethlon Medical expects USD3.3m from sale of units
M2 - Thu Nov 27, 6:04AM CST
Medical device company Aethlon Medical (Other OTC:AEMD) reported on Wednesday an agreement to raise approximately USD3.3m from the sale of units at a price of USD0.30 per unit.
Aethlon Medical Announces $3.3 Million Equity Investment
PR Newswire - Wed Nov 26, 4:16PM CST
Aethlon Medical, Inc. (OTCQB:AEMD), announced today that it has entered into a definitive agreement to raise approximately $3.3 million at a price of $0.30 per unit. The investment is being made by one institutional healthcare focused investor. Each unit consists of one common share and one and one-fifth of a common share purchase warrant. Each whole warrant entitles the holder to acquire one common share at a price of $0.30 for a period of five years from closing.
Aethlon ships Hemopurifiers to Nebraska Med Center
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 9:14AM CST
Aethlon Medical Announces First Hemopurifier® Shipment To Support the Treatment of Ebola in the United States
PR Newswire - Wed Nov 26, 7:30AM CST
Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease and cancer, today announced the first shipment of Hemopurifier® therapy as a candidate to treat future Ebola virus infections in the United States. The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals.
Medical Advances & Technology Challenges Fueling Volume Into Small Cap Stocks
ACCESSWIRE - Tue Nov 25, 7:01AM CST
Boca Raton, FL / ACCESSWIRE / November 25, 2014 / 2015 is just around the corner and yet futuristic views are not so far away. Medical technology moves at great strides forward while the Digital Communications continue to present challenges and opportunities.
